APN01 for COVID-19

Home

APN01 has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.

APN01, alunacedase alfa, soluble ACE2, RhACE2-APN01 Submit Updates

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.biorxiv.org/content/10.1101/2021.09.10.459744v1.full.pdf (In Vitro)

https://clinicaltrials.gov/ct2/show/NCT04335136

https://www.sciencedirect.com/science/article/abs/pii/S0040595721002043

https://www.sciencedirect.com/science/article/pii/S0953620521003071

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit